#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
I need the article summary to complete this task. You’ve provided the title but the summary field is empty. Please share the article summary so I can write the 2-3 sentences explaining its clinical relevance.
A longitudinal study demonstrates that adolescent cannabis use is associated with a doubled risk of psychosis in young adulthood, with the relationship appearing dose and frequency dependent. This finding is particularly significant given the rising potency of cannabis products available today and the ongoing normalization of use among teenagers in jurisdictions where the drug has been legalized. The increased psychosis risk likely reflects both the vulnerability of the developing adolescent brain to cannabinoid effects and potential unmasking of underlying psychotic predisposition in genetically susceptible individuals. Clinicians should consider this evidence when counseling adolescent patients and families about cannabis use, especially those with personal or family histories of psychotic disorders. For prescribing physicians considering cannabis for adult patients, the adolescent data underscores the importance of screening for early-life exposure and psychiatric risk factors. The practical takeaway is that clinicians should actively discourage cannabis use in teenagers and counsel families that delaying use until after neurodevelopmental maturation substantially reduces the psychosis risk profile.
“The epidemiological evidence is now sufficiently robust that I counsel all adolescent patients and their families that cannabis use during the critical neurodevelopmental window carries a genuine risk for psychotic illness, particularly in those with genetic vulnerability, and this conversation needs to happen before use begins rather than after symptoms emerge.”
🧠 This epidemiological finding of approximately doubled psychosis risk associated with adolescent cannabis use aligns with existing literature suggesting vulnerable developmental windows, though clinicians should note that correlation does not establish causation and that reverse causality (prodromal symptoms driving use) remains a plausible alternative explanation. The absolute risk increase depends heavily on baseline psychosis prevalence, individual genetic vulnerability, cannabis potency and frequency of use, and concurrent substance use or mental health conditions, all of which vary substantially across populations and individual patients. Rather than applying a blanket prevention message, clinicians caring for adolescents should assess personal and family psychiatric history when counseling about cannabis risks, recognizing that youth with established psychotic spectrum disorders, first-degree relatives with psychosis, or early psychotic symptoms face materially higher risk. For those already using cannabis, open, nonjudgmental inquiry about frequency, mode of use, and emerging mental health symptoms may enable earlier detection
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it:
